Accelovance (now Linical Accelovance Group)

Accelovance is an award winning, clinical development Contract Research Organization (CRO) focused on oncology, vaccine, and general medicine Phase I-IV programs. Providing a full complement of global CRO services to pharmaceutical companies, biotechs; Accelovance supports client needs by leveraging operational knowledge and successful results including study execution, resourcing, pharmacovigilance/safety, site identification, and patient recruitment strategies. Unique in comparison to most CROs, Accelovance provides complete clinical trial understanding and expertise by leveraging knowledge gained from our investigative site network subsidiary (Optimal Research), a US site management organization. The network includes wholly-owned research centers and a network of pediatric and oncology-focused clinical sites, enabling Optimal to conduct pediatric and oncology research as well as healthy volunteer and general population studies. These sites are structured for productivity – combining proven patient recruitment efforts with properly resourced staff and engaged/experienced Principal Investigators. Accelovance also owns and operates a Clinical Call Center that provides engagement solutions that assist in recruitment, retention, and surveillance. The knowledge gained from working closely with Optimal, coupled with our Clinical Call Center solution, and the therapeutic talent and experience of our team members; creates predictable, controlled enrollment and retention of quality patients that ensures study success.Accelovance is headquartered in Rockville, MD, and has offices in Stuart, FL; Chicago, IL; Durham, NC; Peoria, IL; Philadelphia, PA; Beijing, China; Cambridge, UK; Wales, UK; Moscow, Russia; and Jerusalem, Israel. For more information about Accelovance, visit our Web site at www.accelovance.com.